Therapeutic potential of peptide deformylase inhibitors

被引:32
作者
Chen, D [1 ]
Yuan, Z [1 ]
机构
[1] Vicuron Pharmaceut, Fremont, CA 94555 USA
关键词
anticancer; antimalarial; deformylase inhibitor; metallohydrolase; new antibacterial drug; resistance; respiratory tract infection;
D O I
10.1517/13543784.14.9.1107
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Peptide deformylase (PDF) is an attractive target for antibacterial drug discovery. Progress in the biological characterisation of the enzyme, coupled with newly obtained mechanistic and structural insight, enabled the pharmaceutical industry to discover potent PDF inhibitors that can be considered as clinical development candidates for this new class of antibacterial agents. The in vitro and in vivo data for several lead PDF inhibitors suggest that the current PDF inhibitors are most suitable for the treatment of respiratory tract infections and they are not cross-resistant to the current clinically used antibiotics. Two PDF inhibitors, BB-83698 and VIC-104959, have progressed to Phase I clinical trials by intravenous and oral administration, respectively. Both of these compounds show promising in vitro and in vivo efficacy and an excellent safety profile. The pharmacokinetics in humans for both of the compounds suggest the possibility of a twice-daily dosing regimen for clinical use. Thus far, all of the data suggest a promising future for this new class of antibacterial agents.
引用
收藏
页码:1107 / 1116
页数:10
相关论文
共 65 条
[1]   ON RELEASE OF FORMYL GROUP FROM NASCENT PROTEIN [J].
ADAMS, JM .
JOURNAL OF MOLECULAR BIOLOGY, 1968, 33 (03) :571-&
[2]   Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents [J].
Apfel, C ;
Banner, DW ;
Bur, D ;
Dietz, M ;
Hirata, T ;
Hubschwerlen, C ;
Locher, H ;
Page, MGP ;
Pirson, W ;
Rossé, G ;
Specklin, JL .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (12) :2324-2331
[3]   Peptide deformylase as an antibacterial drug target:: Target validation and resistance development [J].
Apfel, CM ;
Locher, H ;
Evers, S ;
Takács, B ;
Hubschwerlen, C ;
Pirson, W ;
Page, MGP ;
Keck, W .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1058-1064
[4]   Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia [J].
Azoulay-Dupuis, E ;
Mohler, J ;
Bédos, JP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :80-85
[5]  
BOULAROT A, 2004, CURR OPIN INVESTIG D, V5, P806
[6]   In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens [J].
Bowker, KE ;
Noel, AR ;
MacGowan, AP .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 (06) :557-561
[7]   Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center [J].
Bozdogan, B ;
Esel, D ;
Whitener, C ;
Browne, FA ;
Appelbaum, PC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (05) :864-868
[8]   Characterization of an eukaryotic peptide deformylase from Plasmodium falciparum [J].
Bracchi-Ricard, V ;
Nguyen, KT ;
Zhou, Y ;
Rajagopalan, PTR ;
Chakrabarti, D ;
Pei, D .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 396 (02) :162-170
[9]  
BRACKEN K, 2005, 7 ANN SUP SUP C LOND, P7
[10]   Crystal structure of the Escherichia coli peptide deformylase [J].
Chan, MK ;
Gong, WM ;
Rajagopalan, PTR ;
Hao, B ;
Tsai, CM ;
Pei, DH .
BIOCHEMISTRY, 1997, 36 (45) :13904-13909